Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses Upon SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Overview
Authors
Affiliations
B and T cell responses were evaluated in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) after 1 or 2 weeks of methotrexate (MTX) withdrawal following each COVID-19 vaccine dose and compared with those who maintained MTX. Adult RA and PsA patients treated with MTX were recruited and randomly assigned to 3 groups: MTX-maintenance (n = 72), MTX-withdrawal for 1 week (n = 71) or MTX-withdrawal for 2 weeks (n = 73). Specific antibodies to several SARS-CoV-2 antigens and interferon (IFN)-γ and interleukin (IL)-21 responses were assessed. MTX withdrawal in patients without previous COVID-19 was associated with higher levels of anti-RBD IgG and neutralising antibodies, especially in the 2-week withdrawal group and with higher IFN-γ secretion upon stimulation with pools of SARS-CoV-2 S peptides. No increment of RA/PsA relapses was detected across groups. Our data indicate that two-week MTX interruption following COVID-19 vaccination in patients with RA or PsA improves humoral and cellular immune responses.
Dominguez-Casas L, Ferraz-Amaro I, Castaneda S, Blanco R J Clin Med. 2025; 14(4).
PMID: 40004702 PMC: 11856632. DOI: 10.3390/jcm14041174.
Kummer L, Blanco L, Kreher C, Bos A, Kuijper L, Verstegen N RMD Open. 2024; 10(4).
PMID: 39375177 PMC: 11459311. DOI: 10.1136/rmdopen-2024-004664.
Torres-Rufas M, Vicente-Rabaneda E, Cardenoso L, Gutierrez A, Bong D, Valero-Martinez C Vaccines (Basel). 2024; 12(6).
PMID: 38932401 PMC: 11209506. DOI: 10.3390/vaccines12060672.